All In Biotech

Drug Trial Radar · NCT07086755

Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury

Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,100

Planned (sponsor's estimate)

Start

Oct 23, 2025

Primary completion

May 31, 2031

Study completion May 31, 2031

Sponsor

Lead sponsor
Paul PotnuruAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Akebia Therapeutics
First posted
Jul 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the efficacy and safety of vadadustat for treating hospitalized patients with nonintubated Acute Respiratory Distress Syndrome (ARDS) secondary to pathogen-associated lung injury.

Conditions

  • Nonintubated Acute Respiratory Distress Syndrome (ARDS)
  • Pathogen-associated Lung Injury

Interventions

  • Vadadustat 900mgDrug

    Participants will receive 900mg vadadustat (as oral tablets) daily for 14 days or until the date of discharge, whichever comes first, at approximately the same time each day without regard for timing of meals.

  • Vadadustat 1200mgDrug

    Participants will receive 1200mg vadadustat (as oral tablets) daily for 14 days or until the date of discharge, whichever comes first, at approximately the same time each day without regard for timing of meals.

  • PlaceboDrug

    Participants will matching placebo (as oral tablets) daily for 14 days or until the date of discharge, whichever comes first, at approximately the same time each day without regard for timing of meals.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Win ratio for hierarchical composite endpoint based on death, duration of mechanical ventilation or ECMO, and duration of high-flow nasal oxygenation or non-invasive ventilationTime frame: from the time of enrollment to 28 days after enrollment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The University of Texas Health Science Center at Houston

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.